Skip to main content

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
Français FR
Home Home

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process
Français FR

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
  • Home /
  • Listing 3 - Actual negotiations

Listing 3 - Actual negotiations

Search by drug, manufacturer, or indication

Displaying 421 - 430 of 1165

Dayvigo (lemborexant)

Status:

Concluded without agreement

Manufacturer:

Eisai Limited

Indication:

Insomnia

Last updated September 29, 2023

Nexviazyme (avalglucosidase alfa)

Status:

Concluded without agreement

Manufacturer:

Sanofi-Aventis Canada Inc.

Indication:

Late-Onset Pompe Disease

Last updated September 29, 2023

Rinvoq (upadacitinib)

Status:

Concluded with an LOI

Manufacturer:

AbbVie Corporation

Indication:

Atopic dermatitis

Last updated September 19, 2023

Tezspire (tezepelumab)

Status:

Concluded with an LOI

Manufacturer:

AstraZeneca Canada Inc.

Indication:

Severe asthma, add-on maintenance treatment in adults and adolescents 12 years and older

Last updated September 15, 2023

Dificid (fidaxomicin)

Status:

Concluded with an LOI

Manufacturer:

Merck Canada Inc.

Indication:

Clostridium difficile infection

Last updated September 14, 2023

Cabometyx (cabozantinib)

Status:

Concluded with an LOI

Manufacturer:

Ipsen Biopharmaceuticals Canada, Inc.

Indication:

Differentiated thyroid carcinoma (DTC), locally advanced or metastatic, in adult patients who are radioactive iodine-refractory (RAI-R) or ineligible, that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy

Last updated September 14, 2023

Tremfya (guselkumab)

Status:

Concluded with an LOI

Manufacturer:

Janssen Inc.

Indication:

Psoriasis, moderate to severe plaque

Last updated August 21, 2023

Tremfya (guselkumab)

Status:

Concluded with an LOI

Manufacturer:

Janssen Inc.

Indication:

Psoriatic Arthritis

Last updated August 8, 2023

Minjuvi (tafasitamab)

Status:

Concluded with an LOI

Manufacturer:

Incyte Biosciences Canada Corporation

Indication:

Diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS), relapsed or refractory, including DLBCL arising from low grade lymphoma, in adult patients who are not eligible for autologous stem cell transplant (in combination with lenalidomide)

Last updated August 8, 2023

Zepzelca (lurbinectedin)

Status:

Negotiations were not pursued

Manufacturer:

Jazz Pharmaceuticals Canada Inc.

Indication:

Stage III or metastatic small cell lung cancer (SCLC) in adult patients who have progressed on or after platinum-containing therapy

Last updated August 4, 2023

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 41
  • Page 42
  • Current page 43
  • Page 44
  • Page 45
  • …
  • Next page Next ›
  • Last page Last »

Page updated: February 12, 2026

Our team is located across the country, on the ancestral and unceded territories of Canada’s Indigenous Peoples. We recognize their inherent and treaty rights, and we’re grateful to stand, live, and work on these lands.

pan-Canadian Pharmaceutical Association

General inquiries: Email us

Footer Navigation

  • Inside the pCPA
    • Who we are
    • What we do
    • Our vision and strategy
    • Governance
    • Members
  • Insights and updates
    • Our role
    • Drugs we negotiate
    • Performance dashboard
    • News
    • Glossary
  • Negotiations
    • Recent negotiation activity
    • Standard negotiations
    • Expedited pathways
    • Biosimilar drugs
    • Brand-name drugs
    • Generic Drugs

Footer secondary

  • Browse negotiations
  • Careers
  • Contact us
  • News

Copyright © 2026 pan-Canadian Pharmaceutical Alliance. All rights reserved.

Footer Utility

  • Privacy Policy
  • Terms of use